The loss of CB1 in mouse liver or the application of CB1 antagonists can reduce hepatic steatosis and insulin resistance [72,73], decrease inflammasome activation, and improve inflammatory markers [74]. The gene discussed is CNR1; the disease is fatty liver disease.